Articles related to ADJUVANT TREATMENT

In a significant shift, a new phase 3 trial suggests reconsidering adjuvant radiotherapy after radical prostatectomy, as many patients may not require it long-term, potentially reducing morbidity risks.

The IDEA study’s findings have led to a notable change in the treatment of stage III colon cancer, with a shift towards a 3-month duration using CAPOX. Explore the detailed analysis and its implications for your practice.

Explore the detailed findings of a recent study that highlights the impact of treatment interruptions on survival rates in triple-negative breast cancer patients undergoing adjuvant radiotherapy.

In this multi-institutional study, AT significantly increased progression-free and overall survival in 430 patients with node-negative (N0) disease after NAT for localized pancreatic cancer (4.1 vs 2.1 and 5.3 vs 3.5 years, respectively). Patients who received neoadjuvant radiation had their overall survival benefit scaled back, while patients with perineural invasion saw an increase.

In patients with stage IIIB-D or IV melanoma, adjuvant nivolumab with ipilimumab did not increase recurrence-free survival compared to nivolumab monotherapy. Both treatment regimens’ safety and health-related quality of life were similar with earlier research.

It is well recognized that about 30% of people with epilepsy are resistant to dual drug therapy and that selection of a second or later drug is based more on experience than empirical evidence. Drs. Fields and Marcuse of the Icahn School of Medicine discuss the current status of research and what variables will help guide antileptic selection in resistant cases.